product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), PE, eBioscience™
catalog :
12-9908-41
quantity :
25 Tests
price :
US 152
clonality :
monoclonal
host :
mouse
conjugate :
PE
clone name :
DJR2-4 (7-8)
reactivity :
human
application :
flow cytometry
more info or order :
Invitrogen product webpage
citations: 53
Published Application/Species/Sample/DilutionReference
  • flow cytometry; human; fig 4c
Fauster A, Rebsamen M, Willmann K, César Razquin A, Girardi E, Bigenzahn J, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138-1155 pubmed publisher
  • flow cytometry; human; fig s2
Liesche C, Venkatraman L, Aschenbrenner S, Grosse S, Grimm D, Eils R, et al. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol. 2016;16:17 pubmed publisher
Chiawpanit C, Panwong S, Sawasdee N, Yenchitsomanus P, Panya A. Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells. Biology (Basel). 2022;11: pubmed publisher
Belkahla S, Brualla J, Fayd Herbe De Maudave A, Falvo P, Allende Vega N, Constantinides M, et al. The metabolism of cells regulates their sensitivity to NK cells depending on p53 status. Sci Rep. 2022;12:3234 pubmed publisher
Sawasdee N, Wattanapanitch M, Thongsin N, Phanthaphol N, Chiawpanit C, Thuwajit C, et al. Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors. Int J Mol Med. 2022;49: pubmed publisher
Allende Vega N, Marco Brualla J, Falvo P, Alexia C, Constantinides M, De Maudave A, et al. Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). Sci Rep. 2022;12:1341 pubmed publisher
An Y, Jeon J, Sun L, Derakhshan A, Chen J, Carlson S, et al. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas. Sci Rep. 2021;11:6392 pubmed publisher
Khawaja H, Campbell A, Roberts J, Javadi A, O Reilly P, McArt D, et al. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death Dis. 2020;11:930 pubmed publisher
Johnston M, Nicoll J, Redmond K, Smyth P, Greene M, McDaid W, et al. DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. J Control Release. 2020;324:610-619 pubmed publisher
Wang Y, Guo S, Li D, Tang Y, Li L, Su L, et al. YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells. Cell Death Dis. 2020;11:242 pubmed publisher
Ivanov V, Wu J, Wang T, Hei T. Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and γ-irradiation in human glioblastoma cells. Oncotarget. 2019;10:825-846 pubmed publisher
Ivanov V, Wu J, Hei T. Regulation of human glioblastoma cell death by combined treatment of cannabidiol, ?-radiation and small molecule inhibitors of cell signaling pathways. Oncotarget. 2017;8:74068-74095 pubmed publisher
Milutinovic S, Kashyap A, Yanagi T, Wimer C, Zhou S, O Neil R, et al. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther. 2016;15:114-24 pubmed publisher
Reddy A, Growney J, Wilson N, Emery C, Johnson J, Ward R, et al. Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. PLoS ONE. 2015;10:e0138486 pubmed publisher
Hwang M, Li X, Kim J, Jeong S, Lee S, Lee J, et al. Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro. PLoS ONE. 2015;10:e0136209 pubmed publisher
Liu Y, Hawkins O, Vilgelm A, Pawlikowski J, Ecsedy J, Sosman J, et al. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clin Cancer Res. 2015;21:5338-48 pubmed publisher
Chandrasekaran S, Marshall J, Messing J, Hsu J, King M. TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids. PLoS ONE. 2014;9:e111487 pubmed publisher
Redjal N, Zhu Y, Shah K. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells. 2015;33:101-10 pubmed publisher
Boyko Fabian M, Niehr F, Distel L, Budach V, Tinhofer I. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. PLoS ONE. 2014;9:e98867 pubmed publisher
Aronin A, Amsili S, Prigozhina T, Tzdaka K, Rachmilewitz J, Shani N, et al. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth. PLoS ONE. 2013;8:e77050 pubmed publisher
Zhang N, Wang X, Huo Q, Li X, Wang H, Schneider P, et al. The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer. J Biol Chem. 2013;288:9396-407 pubmed publisher
Woldemichael G, Turbyville T, Vasselli J, Linehan W, McMahon J. Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A. Neoplasia. 2012;14:771-7 pubmed
Bagci Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene. 2013;32:2818-27 pubmed publisher
Piechocki M, Wu G, Jones R, Jacob J, Gibson H, Ethier S, et al. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. Int J Cancer. 2012;131:2562-72 pubmed publisher
Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat. 2012;134:139-55 pubmed publisher
Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to V?9V?2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 2012;30:824-30 pubmed publisher
Dompe N, Rivers C, Li L, Cordes S, Schwickart M, Punnoose E, et al. A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proc Natl Acad Sci U S A. 2011;108:E943-51 pubmed publisher
Hanada K, Wang Q, Inozume T, Yang J. Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood. 2011;117:4816-25 pubmed publisher
Fu L, Lin Y, Elrod H, Yue P, Oh Y, Li B, et al. c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Mol Cancer. 2010;9:315 pubmed publisher
Cabezón R, Sintes J, Llinàs L, Benitez Ribas D. Analysis of HLDA9 mAbs on plasmacytoid dendritic cells. Immunol Lett. 2011;134:167-73 pubmed publisher
Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, et al. TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2010;11:192 pubmed publisher
Zoog S, Ma C, Kaplan Lefko P, Hawkins J, Moriguchi J, Zhou L, et al. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry A. 2010;77:849-60 pubmed publisher
Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol. 2010;12:687-700 pubmed publisher
Prasmickaite L, Engesaeter B, Skrbo N, Hellenes T, Kristian A, Oliver N, et al. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE. 2010;5:e10731 pubmed publisher
Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, et al. Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. J Virol. 2010;84:2762-73 pubmed publisher
Sun X, Canda Sánchez A, Manjeri G, Cohen G, Pinkoski M. Phenylarsine oxide interferes with the death inducing signaling complex and inhibits tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Exp Cell Res. 2009;315:2453-62 pubmed publisher
Ames E, Hallett W, Murphy W. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol. 2009;155:504-13 pubmed publisher
Balsas P, López Royuela N, Galán Malo P, Anel A, Marzo I, Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol. 2009;77:804-12 pubmed publisher
Zou W, Yue P, Khuri F, Sun S. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res. 2008;68:7484-92 pubmed publisher
Song J, Kandasamy K, Kraft A. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008;283:25003-13 pubmed publisher
Lin Y, Chen S, Yue P, Zou W, Benbrook D, Liu S, et al. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008;68:5335-44 pubmed publisher
Verbrugge I, de Vries E, Tait S, Wissink E, Walczak H, Verheij M, et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene. 2008;27:574-84 pubmed
Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri F, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007;67:4981-8 pubmed
Sun S, Liu X, Zou W, Yue P, Marcus A, Khuri F. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem. 2007;282:18800-9 pubmed
Vanoosten R, Earel J, Griffith T. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis. 2007;12:561-71 pubmed
Zou W, Liu X, Yue P, Khuri F, Sun S. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther. 2007;6:99-106 pubmed
Mattarollo S, Kenna T, Nieda M, Nicol A. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity. Int J Cancer. 2006;119:1630-7 pubmed
VanOosten R, Earel J, Griffith T. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006;13:628-32 pubmed
Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology. 2006;43:362-72 pubmed
Earel J, Vanoosten R, Griffith T. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006;66:499-507 pubmed
Longley D, Wilson T, McEwan M, Allen W, McDermott U, Galligan L, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene. 2006;25:838-48 pubmed
Hyer M, Croxton R, Krajewska M, Krajewski S, Kress C, Lu M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005;65:4799-808 pubmed
Zou W, Liu X, Yue P, Zhou Z, Sporn M, Lotan R, et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004;64:7570-8 pubmed
product information
Product Type :
Antibody
Product Name :
CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), PE, eBioscience™
Catalog # :
12-9908-41
Quantity :
25 Tests
Price :
US 152
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Mouse
Reactivity :
Human
Applications :
Flow Cytometry: 5 µL (0.25 µg)/test
Species :
Human
Clone :
DJR2-4 (7-8)
Isotype :
IgG1, kappa
Storage :
4° C, store in dark, DO NOT FREEZE!
Description :
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 5 µL (0.25 µg)/test
Aliases :
apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; dr-5; Fas-like protein; Killer; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA